Estrella Immunopharma, Inc.
ESLA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $34,719 | $33,547 | $44,017 | $42,002 |
| - Cash | $1,317 | $421 | $917 | $1,798 |
| + Debt | $4 | $0 | $0 | $0 |
| Enterprise Value | $33,406 | $33,125 | $43,100 | $40,204 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$5,544 | -$2,104 | -$1,050 | -$3,377 |
| % Margin | – | – | – | – |
| Net Income | -$5,545 | -$2,104 | -$1,050 | -$3,377 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.15 | -0.058 | -0.029 | -0.093 |
| % Growth | -157.7% | -103.5% | 69.3% | – |
| Operating Cash Flow | -$415 | -$466 | -$896 | -$2,217 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$415 | -$466 | -$896 | -$2,217 |